Azadeh Cheraghchi-Bashi

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

Chrysiis Michaloglou, Claire Crafter, Oona Delpuech et al. · Molecular Cancer Therapeutics · 2018 · 190 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana R�os et al. · Cancer Research · 2023 · 60 citations · Full text

Medicine, Oncology, Pharmacology +16

A putative biomarker signature for clinically effective AKT inhibition: correlation of <i>in vitro</i>, <i>in vivo</i> and clinical data identifies the importance of modulation of the mTORC1 pathway

Azadeh Cheraghchi-Bashi, Christine A. Parker, Edward Curry et al. · Oncotarget · 2015 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC

Thomas G. Hayhow, Beth Williamson, Mandy Lawson et al. · Communications Biology · 2024 · 22 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16